Omeros (OMER) Revenue & Revenue Breakdown
Omeros Revenue Highlights
00
Omeros Revenue by Period
Omeros Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $73.81M | -33.98% |
| 2019-12-31 | $111.81M | 274.33% |
| 2018-12-31 | $29.87M | -53.93% |
| 2017-12-31 | $64.83M | 55.77% |
| 2016-12-31 | $41.62M | 208.07% |
| 2015-12-31 | $13.51M | 2406.31% |
| 2014-12-31 | $539.00K | -66.31% |
| 2013-12-31 | $1.60M | -73.43% |
| 2012-12-31 | $6.02M | 33.11% |
| 2011-12-31 | $4.52M | 114.92% |
| 2010-12-31 | $2.10M | 45.78% |
| 2009-12-31 | $1.44M | 23.42% |
| 2008-12-31 | $1.17M | -39.16% |
| 2007-12-31 | $1.92M | 861.50% |
| 2006-12-31 | $200.00K | 100.00% |
| 2005-12-31 | - | - |
Omeros generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Omeros Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $412.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.37M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $-79.89M | -366.26% |
| 2021-09-30 | $30.00M | 4.10% |
| 2021-06-30 | $28.82M | 36.85% |
| 2021-03-31 | $21.06M | 98.09% |
| 2020-12-31 | $10.63M | -59.29% |
| 2020-09-30 | $26.11M | 93.01% |
| 2020-06-30 | $13.53M | -42.52% |
| 2020-03-31 | $23.54M | -29.57% |
| 2019-12-31 | $33.42M | 11.93% |
| 2019-09-30 | $29.86M | 11.60% |
| 2019-06-30 | $26.75M | 22.84% |
| 2019-03-31 | $21.78M | -1.08% |
| 2018-12-31 | $22.02M | 377.80% |
| 2018-09-30 | $4.61M | 178.43% |
| 2018-06-30 | $1.66M | 4.22% |
| 2018-03-31 | $1.59M | -88.46% |
| 2017-12-31 | $13.76M | -36.47% |
| 2017-09-30 | $21.66M | 26.28% |
| 2017-06-30 | $17.15M | 39.93% |
| 2017-03-31 | $12.26M | -5.02% |
| 2016-12-31 | $12.90M | 14.31% |
| 2016-09-30 | $11.29M | 12.84% |
| 2016-06-30 | $10.00M | 34.84% |
| 2016-03-31 | $7.42M | 11.15% |
| 2015-12-31 | $6.67M | 104.82% |
| 2015-09-30 | $3.26M | 2.26% |
| 2015-06-30 | $3.19M | 721.39% |
| 2015-03-31 | $388.00K | 115.56% |
| 2014-12-31 | $180.00K | -15.89% |
| 2014-09-30 | $214.00K | 375.56% |
| 2014-06-30 | $45.00K | -55.00% |
| 2014-03-31 | $100.00K | -40.83% |
| 2013-12-31 | $169.00K | -13.78% |
| 2013-09-30 | $196.00K | 40.00% |
| 2013-06-30 | $140.00K | -87.21% |
| 2013-03-31 | $1.09M | -30.83% |
| 2012-12-31 | $1.58M | 11.71% |
| 2012-09-30 | $1.42M | -7.14% |
| 2012-06-30 | $1.53M | 2.01% |
| 2012-03-31 | $1.50M | 30.88% |
| 2011-12-31 | $1.14M | 15.81% |
| 2011-09-30 | $987.00K | -14.55% |
| 2011-06-30 | $1.16M | -6.78% |
| 2011-03-31 | $1.24M | 26.95% |
| 2010-12-31 | $976.00K | 284.25% |
| 2010-09-30 | $254.00K | -48.89% |
| 2010-06-30 | $497.00K | 31.48% |
| 2010-03-31 | $378.00K | -12.90% |
| 2009-12-31 | $434.00K | -1.81% |
| 2009-09-30 | $442.00K | 19.14% |
| 2009-06-30 | $371.00K | 88.32% |
| 2009-03-31 | $197.00K | 8.84% |
| 2008-12-31 | $181.00K | -63.87% |
| 2008-09-30 | $501.00K | - |
Omeros generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Omeros Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FOLD | Amicus Therapeutics | $528.29M | $125.25M |
| MIRM | Mirum Pharmaceuticals | $336.89M | $99.41M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $71.36M |
| LGND | Ligand Pharmaceuticals | $167.13M | $42.81M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
| GOSS | Gossamer Bio | $114.70M | $9.89M |
| ENTA | Enanta Pharmaceuticals | $67.64M | $14.93M |
| STOK | Stoke Therapeutics | $36.55M | $22.61M |
| CNTB | Connect Biopharma | $26.03M | - |
| RNA | Avidity Biosciences | $10.90M | $2.97M |
| CRNX | Crinetics Pharmaceuticals | $1.04M | - |
| DSGN | Design Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | $170.64M |
| RVMD | Revolution Medicines | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| LYEL | Lyell Immunopharma | - | $11.00K |
| OMER | Omeros | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |